{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:24:55Z","timestamp":1785795895054,"version":"3.56.0"},"reference-count":12,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The focus of this Special Issue of Pharmaceuticals is on the design, synthesis, and molecular mechanism of action of novel antitumor, drugs with a special emphasis on the relationship between the chemical structure and the biological activity of the molecules. This Special Issue also provides an understanding of the biologic and genotypic context in which targets are selected for oncology drug discovery, thus providing a rationalization for the biological activity of these drugs and guiding the design of more effective agents. In this Special Issue of Pharmaceuticals dedicated to anticancer drugs, we present a selection of preclinical research papers including both traditional chemotherapeutic agents and newer more targeted therapies and biological agents. We have included articles that report the design of small molecules with promising anticancer activity as tubulin inhibitors, vascular targeting agents, and topoisomerase targeting agents, alongside a comprehensive review of clinically successful antibody-drug conjugates used in cancer treatment.<\/jats:p>","DOI":"10.3390\/ph12030134","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T03:17:57Z","timestamp":1568603877000},"page":"134","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Special Issue \u201cAnticancer Drugs\u201d"],"prefix":"10.3390","volume":"12","author":[{"given":"Mary J.","family":"Meegan","sequence":"first","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, 2 DO2R590 Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5660-4944","authenticated-orcid":false,"given":"Niamh M.","family":"O\u2019Boyle","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, 2 DO2R590 Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,16]]},"reference":[{"key":"ref_1","unstructured":"(2019, September 11). The International Agency for Research on Cancer, Available online: https:\/\/www.who.int\/cancer\/PRGlobocanFinal.pdf."},{"key":"ref_2","unstructured":"(2019, September 11). 2018 New Drug Therapy Approvals Impact, Available online: https:\/\/www.fda.gov\/files\/drugs\/published\/New-Drug-Therapy-Approvals-2018_3.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Makharza, S.A., Cirillo, G., Vittorio, O., Valli, E., Voli, F., Farfalla, A., Curcio, M., Iemma, F., Nicoletta, F.P., and El-Gendy, A.A. (2019). Magnetic Graphene Oxide Nanocarrier for Targeted Delivery of Cisplatin: A Perspective for Glioblastoma Treatment. Pharmaceuticals, 12.","DOI":"10.3390\/ph12020076"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Buckley, A.M., Bibby, B.A., Dunne, M.R., Kennedy, S.A., Davern, M.B., Kennedy, B.N., Maher, S.G., and O\u2019Sullivan, J. (2019). Characterisation of an Isogenic Model of Cisplatin Resistance in Oesophageal Adenocarcinoma Cells. Pharmaceuticals, 12.","DOI":"10.3390\/ph12010033"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wang, S., Malebari, A.M., Greene, T.F., O\u2019Boyle, N.M., Fayne, D., Nathwani, S.M., Twamley, B., McCabe, T., Keely, N.O., and Zisterer, D.M. (2019). 3-Vinylazetidin-2-Ones: Synthesis, Antiproliferative and Tubulin Destabilizing Activity in MCF-7 and MDA-MB-231 Breast Cancer Cells. Pharmaceuticals, 12.","DOI":"10.3390\/ph12020056"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Miller, C.M., O\u2019Sullivan, E.C., and McCarthy, F.O. (2019). Novel 11-Substituted Ellipticines as Potent Anticancer Agents with Divergent Activity against Cancer Cells. Pharmaceuticals, 12.","DOI":"10.3390\/ph12020090"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"De Miranda, J.A.L., Barretto, J.E.F., Martins, D.S., de Souza Pimentel, P.V., da Silva Costa, D.V., Silva, R.R., de Souza, L.K.M., de Lima, C.N., Rocha, J.A., and de Freitas, A.P.F. (2019). Protective Effect of Cashew Gum (Anacardium occidentale L.) on 5-Fluorouracil-Induced Intestinal Mucositis. Pharmaceuticals, 12.","DOI":"10.3390\/ph12020051"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Cancio, M., Camats, N., Fl\u00fcck, C.E., Zalewski, A., Dick, B., Frey, B.M., Monn\u00e9, R., Tor\u00e1n, N., Aud\u00ed, L., and Pandey, A.V. (2018). Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency. Pharmaceuticals, 11.","DOI":"10.3390\/ph11020037"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"O\u2019Neill, H., Malik, V., Johnston, C., Reynolds, J.V., and O\u2019Sullivan, J. (2019). Can the Efficacy of [18F]FDG-PET\/CT in Clinical Oncology Be Enhanced by Screening Biomolecular Profiles?. Pharmaceuticals, 12.","DOI":"10.3390\/ph12010016"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pannunzio, A., and Coluccia, M. (2018). Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry Literature. Pharmaceuticals, 11.","DOI":"10.3390\/ph11040101"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/ph11020032","article-title":"Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications","volume":"11","author":"Dan","year":"2018","journal-title":"Pharmaceuticals"},{"key":"ref_12","first-page":"256","article-title":"Cancer biomarker discovery and validation","volume":"4","author":"Goossens","year":"2015","journal-title":"Transl. Cancer Res."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/12\/3\/134\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:20:26Z","timestamp":1760188826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/12\/3\/134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,16]]},"references-count":12,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["ph12030134"],"URL":"https:\/\/doi.org\/10.3390\/ph12030134","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,16]]}}}